Targeting ENPP1 for cancer immunotherapy: Killing two birds with one stone

Huang, Ruilei; Ning, Qian; Zhao, Jihui; Zhao, Xuhong; Zeng, Luting; Yi, Yi; Tang, Shengsong

doi:10.1016/j.bcp.2023.116006

Search citation statements

Order By: Relevance

Paper Sections

Select...

Enpp11

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blocking ENPP1 can potentially restore the effectiveness of the STING pathway, thereby enhancing immunemediated tumor suppression. This can be particularly effective when used in combination with other therapies such as checkpoint inhibitors, radiation therapy, or DNA damage response inhibitors, which could synergize to amplify the antitumor immune response (120,121).…”

Section: Enpp1mentioning

confidence: 99%

From mechanism to therapy: the journey of CD24 in cancer

Zhao,

Wu,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

CD24 is a glycosylphosphatidylinositol-anchored protein that is expressed in a wide range of tissues and cell types. It is involved in a variety of physiological and pathological processes, including cell adhesion, migration, differentiation, and apoptosis. Additionally, CD24 has been studied extensively in the context of cancer, where it has been found to play a role in tumor growth, invasion, and metastasis. In recent years, there has been growing interest in CD24 as a potential therapeutic target for cancer treatment. This review summarizes the current knowledge of CD24, including its structure, function, and its role in cancer. Finally, we provide insights into potential clinical application of CD24 and discuss possible approaches for the development of targeted cancer therapies.

show abstract

Section: Enpp1mentioning

confidence: 99%